{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:27:45Z","timestamp":1768570065634,"version":"3.49.0"},"posted":{"date-parts":[[2025,3,10]]},"group-title":"Neurology","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Spinocerebellar ataxia type 3 (SCA3) is one of the most common dominantly inherited ataxia worldwide. Despite research advances, no approved disease-modifying treatment exists, and management focuses on symptom alleviation and functional capacity maximization. Symptomatic treatment guidelines are scarce, leaving decisions to physicians\u2019 discretion. The lack of studies on SCA3 symptom management hinders therapy standardization. This study investigated medication usage patterns among SCA3 mutation carriers and controls recruited by the multicentric European Spinocerebellar Ataxia Type-3\/Machado-Joseph Disease Initiative (ESMI).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We collected medication data from ESMI cohort participants (n=474), comparing SCA3 mutation carriers (n=344) at different disease stages with controls (n=130). We analysed medication usage based on age and ataxia severity groups as well as research centre locations using the ATC code system for classification.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were significant differences in medication usage between mutation carriers and controls. SCA3 subjects took more vitamins, mineral supplements, and muscle relaxants, and medications targeting the nervous system. Psychoanaleptics and vitamins were introduced earlier in the disease course, with 29.2% and 25.0% of mildly ataxic individuals using such subclasses medications, respectively. Most medications, however, were only initiated during the mid-to-late stages of the disease, coinciding with the onset of most neurological symptoms. There were substantial disparities in medication usage across study centres. No significant impact on disease progression was observed for the medication subclasses more frequently used by SCA3 patients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This is the first study to explore medication usage patterns in SCA3 mutation carriers. Our study provides a comprehensive overview of the medications administered in SCA3 and underscore the importance of collaborative efforts toward achieving standardized clinical practices in the management of this disease.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.03.05.25322961","type":"posted-content","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:25:16Z","timestamp":1741652716000},"source":"Crossref","is-referenced-by-count":0,"title":["The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort"],"prefix":"10.64898","author":[{"given":"Patrick","family":"Silva","sequence":"first","affiliation":[]},{"given":"Marina A.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Laetitia","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Dur\u00e3es","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Cunha","sequence":"additional","affiliation":[]},{"given":"Joana A","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Janu\u00e1rio","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7836-8161","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Oliveiros","sequence":"additional","affiliation":[]},{"given":"Jeannette","family":"H\u00fcbener-Schmid","sequence":"additional","affiliation":[]},{"given":"Jennifer","family":"Faber","sequence":"additional","affiliation":[]},{"given":"Mafalda","family":"Raposo","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Hector","family":"Garcia-Moreno","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Giunti","sequence":"additional","affiliation":[]},{"given":"Lukas","family":"Beichert","sequence":"additional","affiliation":[]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[]},{"given":"Bart P.","family":"van de Warrenburg","sequence":"additional","affiliation":[]},{"given":"Jeroen","family":"de Vries","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Thieme","sequence":"additional","affiliation":[]},{"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[]},{"given":"Heike","family":"Jacobi","sequence":"additional","affiliation":[]},{"given":"Jon","family":"Infante","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Klockgether","sequence":"additional","affiliation":[]},{"name":"ESMI Study Group","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Pereira de Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4076-7516","authenticated-orcid":false,"given":"Magda M.","family":"Santana","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2025032003080725000_2025.03.05.25322961v1.1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1212\/WNL.0000000000011424","article-title":"What Is the Mechanism of Therapeutic and Adverse Effects of Gabapentinoids?","volume":"96","year":"2021","journal-title":"Neurology"},{"key":"2025032003080725000_2025.03.05.25322961v1.2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-11-131","article-title":"Parkinsonian phenotype in Machado-Joseph disease (MJD\/SCA3): a two-case report","volume":"11","year":"2011","journal-title":"BMC Neurol"},{"key":"2025032003080725000_2025.03.05.25322961v1.3","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/acn3.51370","article-title":"Spinocerebellar ataxia clinical trials: opportunities and challenges","volume":"8","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2025032003080725000_2025.03.05.25322961v1.4","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10322"},{"key":"2025032003080725000_2025.03.05.25322961v1.5","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/TCRM.S274122","article-title":"Update on Safety Profiles of Vitamins B1, B6, and B12: A Narrative Review","volume":"16","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2025032003080725000_2025.03.05.25322961v1.6","doi-asserted-by":"publisher","DOI":"10.1086\/301699"},{"key":"2025032003080725000_2025.03.05.25322961v1.7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-019-1013-9","article-title":"Guidelines on the diagnosis and management of the progressive ataxias","volume":"14","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025032003080725000_2025.03.05.25322961v1.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0261-1"},{"key":"2025032003080725000_2025.03.05.25322961v1.9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.5664\/jcsm.8308","article-title":"Use of clonazepam in REM sleep behavior disorder: association with fall-related injuries and alternative treatments","volume":"16","year":"2020","journal-title":"J Clin Sleep Med"},{"key":"2025032003080725000_2025.03.05.25322961v1.10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/16501977-2211","article-title":"Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen","volume":"49","year":"2017","journal-title":"J Rehabil Med"},{"key":"2025032003080725000_2025.03.05.25322961v1.11","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.12.1767"},{"key":"2025032003080725000_2025.03.05.25322961v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afx158"},{"key":"2025032003080725000_2025.03.05.25322961v1.13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22288"},{"key":"2025032003080725000_2025.03.05.25322961v1.14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00415-022-11441-z","article-title":"The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factors\u2019","volume":"270","year":"2023","journal-title":"J Neurol"},{"key":"2025032003080725000_2025.03.05.25322961v1.15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.smrv.2013.03.004","article-title":"What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications","volume":"18","year":"2014","journal-title":"Sleep Med Rev"},{"key":"2025032003080725000_2025.03.05.25322961v1.16","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-013-0531-6"},{"key":"2025032003080725000_2025.03.05.25322961v1.17","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-012-0421-3"},{"key":"2025032003080725000_2025.03.05.25322961v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0074-3"},{"key":"2025032003080725000_2025.03.05.25322961v1.19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2016.03.005","article-title":"Safety and efficacy of valproic acid treatment in SCA3\/MJD patients","volume":"26","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"2025032003080725000_2025.03.05.25322961v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.11.021"},{"key":"2025032003080725000_2025.03.05.25322961v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10516-7"},{"key":"2025032003080725000_2025.03.05.25322961v1.22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/pop.2018.0069","article-title":"Recent Patterns of Multimorbidity Among Older Adults in High-Income Countries","volume":"22","year":"2019","journal-title":"Popul Health Manag"},{"key":"2025032003080725000_2025.03.05.25322961v1.23","first-page":"125273","article-title":"Parkinsonism in spinocerebellar ataxia","volume":"2015","year":"2015","journal-title":"Biomed Res Int"},{"key":"2025032003080725000_2025.03.05.25322961v1.24","doi-asserted-by":"crossref","unstructured":"Rai, S. N. , P. Singh , H. W. M. Steinbusch , E. Vamanu , G. Ashraf , and M. P. Singh . 2021. \u2019The Role of Vitamins in Neurodegenerative Disease: An Update\u2019, Biomedicines, 9.","DOI":"10.3390\/biomedicines9101284"},{"key":"2025032003080725000_2025.03.05.25322961v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.05.005"},{"key":"2025032003080725000_2025.03.05.25322961v1.26","doi-asserted-by":"publisher","DOI":"10.1159\/000358801"},{"key":"2025032003080725000_2025.03.05.25322961v1.27","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3282f7673d"},{"key":"2025032003080725000_2025.03.05.25322961v1.28","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-011-0340-8"},{"key":"2025032003080725000_2025.03.05.25322961v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23698"},{"key":"2025032003080725000_2025.03.05.25322961v1.30","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000219042.60538.92"},{"key":"2025032003080725000_2025.03.05.25322961v1.31","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1212\/WNL.51.6.1603","article-title":"Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome?","volume":"51","year":"1998","journal-title":"Neurology"},{"key":"2025032003080725000_2025.03.05.25322961v1.32","first-page":"CD006009","article-title":"Dopamine agonists for restless legs syndrome","volume":"2011","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025032003080725000_2025.03.05.25322961v1.33","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12311-023-01651-0","article-title":"The Cerebellar Cognitive Affective\/Schmahmann Syndrome Scale in Spinocerebellar Ataxias","volume":"23","year":"2024","journal-title":"Cerebellum"},{"key":"2025032003080725000_2025.03.05.25322961v1.34","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/bcp.14462","article-title":"Medication use among older people in Europe: Implications for regulatory assessment and co-prescription of new medicines","volume":"86","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025032003080725000_2025.03.05.25322961v1.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9076-4"},{"key":"2025032003080725000_2025.03.05.25322961v1.36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40734-016-0047-6","article-title":"Medical treatment of dystonia","volume":"3","year":"2016","journal-title":"J Clin Mov Disord"},{"key":"2025032003080725000_2025.03.05.25322961v1.37","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1007\/s00415-022-11071-5","article-title":"The CCAS-scale in hereditary ataxias: helpful on the group level, particularly in SCA3, but limited in individual patients","volume":"269","year":"2022","journal-title":"J Neurol"},{"key":"2025032003080725000_2025.03.05.25322961v1.38","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380422"},{"key":"2025032003080725000_2025.03.05.25322961v1.39","first-page":"994","article-title":"\u2019Decreased dopamine transporter binding in Machado-Joseph disease\u2019","volume":"41","year":"2000","journal-title":"J Nucl Med"},{"key":"2025032003080725000_2025.03.05.25322961v1.40","first-page":"153","article-title":"Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers","volume":"43","year":"2002","journal-title":"J Nucl Med"},{"key":"2025032003080725000_2025.03.05.25322961v1.41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","article-title":"Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","year":"2018","journal-title":"Neurology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.03.05.25322961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:30:01Z","timestamp":1768509001000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.03.05.25322961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1101\/2025.03.05.25322961","relation":{},"subject":[],"published":{"date-parts":[[2025,3,10]]},"subtype":"preprint"}}